High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer

Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is an aggressive subtype of this disease. Targeted treatment has improved outcome, but there is still a need for new therapeutic strategies as some patients respond poorly to treatment. Our aim was to identify compounds that sub...

Descripción completa

Detalles Bibliográficos
Autores principales: Normann, Lisa Svartdal, Haugen, Mads Haugland, Hongisto, Vesa, Aure, Miriam Ragle, Leivonen, Suvi-Katri, Kristensen, Vessela N., Tahiri, Andliena, Engebraaten, Olav, Sahlberg, Kristine Kleivi, Mælandsmo, Gunhild Mari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882887/
https://www.ncbi.nlm.nih.gov/pubmed/36706086
http://dx.doi.org/10.1371/journal.pone.0280507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882887/
https://www.ncbi.nlm.nih.gov/pubmed/36706086
http://dx.doi.org/10.1371/journal.pone.0280507

Ejemplares similares